Modifier and HCPCS Changes for 2018

The following new and deleted National Level II modifiers and Healthcare Common Procedure Coding System (HCPCS) are effective for dates of service on/after January 1, 2018.

In compliance with the Health Insurance Portability and Accountability Act (HIPAA), CMS eliminated the 3-month grace period for discontinued codes in Change Request (CR) 3093 dated February 6, 2004. Effective for dates of services on/after January 1, 2010, there is no grace period for billing discontinued HCPCS codes.

Note: The inclusion of modifiers or codes on this web page do not necessarily indicate coverage. New modifiers and HCPCS identified as Durable Medical Equipment (DME) are not included in this listing.

X
 

New Modifiers

MODIFIER DESCRIPTION
   FY X-ray taken using computed radiography technology/cassette-based imaging
   JG Drug or biological acquired with 340b drug pricing program discount
   QQ Ordering professional consulted a qualified clinical decision support mechanism for this service and the related data was provided to the furnishing professional
   TB Drug or biological acquired with 340b drug pricing program discount, reported for informational purposes
   X1 Continuous/broad services: for reporting services by clinicians, who provide the principal care for a patient, with no planned endpoint of the relationship; services in this category represent comprehensive care, dealing with the entire scope of patient problems, either directly or in a care coordination role; reporting clinician service examples include, but are not limited to: primary care, and clinicians providing comprehensive care to patients in addition to specialty care
   X2 Continuous/focused services: for reporting services by clinicians whose expertise is needed for the ongoing management of a chronic disease or a condition that needs to be managed and followed with no planned endpoint to the relationship; reporting clinician service examples include but are not limited to: a rheumatologist taking care of the patient's rheumatoid arthritis longitudinally but not providing general primary care services
   X3 Episodic/broad servies: for reporting services by clinicians who have broad responsibility for the comprehensive needs of the patient that is limited to a defined period and circumstance such as a hospitalization; reporting clinician service examples include but are not limited to the hospitalist's services rendered providing comprehensive and general care to a patient while admitted to the hospital
   X4 Episodic/focused services: for reporting services by clinicians who provide focused care on particular types of treatment limited to a defined period and circumstance; the patient has a problem, acute or chronic, that will be treated with surgery, radiation, or some other type of generally time-limited intervention; reporting clinician service examples include but are not limited to, the orthopedic surgeon performing a knee replacement and seeing the patient through the postoperative period
   VM Medicare diabetes prevention program (mdpp) virtual make-up session
   X5 Diagnostic services requested by another clinician: for reporting services by a clinician who furnishes care to the patient only as requested by another clinician or subsequent and related services requested by another clinician; this modifier is reported for patient relationships that may not be adequately captured by the above alternative categories; reporting clinician service examples include but are not limited to, the radiologist's interpretation of an imaging study requested by another clinician
   92 Alternative laboratory platform testing: when laboratory testing is being performed using a kit or transportable instrument that wholly or in part consists of a single use, disposable analytical chamber, the service may be identified by adding modifier 92 to the usual laboratory procedure code (hiv testing 86701-86703, and 87389). the test does not require permanent dedicated space, hence by its design may be hand carried or transported to the vicinity of the patient for immediate testing at that site, although location of the testing is not in itself determinative of the use of this modifier.
   95 Synchronous telemedicine service rendered via a real-time interactive audio and video telecommunications system: synchronous telemedicine service is defined as a real-time interaction between a physician or other qualified health care professional and a patient who is located at a distant site from the physician or other qualified health care professional. the totality of the communication of information exchanged between the physician or other qualified health care professional and the patient during the course of the synchronous telemedicine service must be of an amount and nature that would be sufficient to meet the key components and/or requirements of the same service when rendered via a face-to-face interaction. modifier 95 may only be appended to the services listed in appendix p. appendix p is the list of cpt codes for services that are typically performed face-to-face, but may be rendered via a real-time (synchronous) interactive audio and video telecommunications system
   97 Rehabilitative services: when a service or procedure that may be either habilitative or rehabilitative in nature is provided for rehabilitative purposes, the physician or other qualified health care professional may add modifier 97 to the service or procedure code to indicate that the service or procedure provided was a rehabilitative service. rehabilitative services help an individual keep, get back, or improve skills and functioning for daily living that have been lost or impaired because the individual was sick, hurt, or disabled

 

New Codes

HCPCS DESCRIPTION
C9014 Injection, cerliponase alfa, 1 mg
C9015 Injection, c-1 esterase inhibitor (human), haegarda, 10 units
C9016 Injection, triptorelin extended release, 3.75 mg
C9024 Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
C9028 Injection, inotuzumab ozogamicin, 0.1 mg
C9029 Injection, guselkumab, 1 mg
C9488 Injection, conivaptan hydrochloride, 1 mg
C9492 Injection, durvalumab, 10 mg
C9493 Injection, edaravone, 1 mg
C9738 Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure)
C9745 Nasal endoscopy, surgical; balloon dilation of eustachian tube
C9746 Transperineal implantation of permanent adjustable balloon continence device, with cystourethroscopy, when performed and/or fluoroscopy, when performed
C9747 Ablation of prostate, transrectal, high intensity focused ultrasound (hifu), including imaging guidance
C9748 Transurethral destruction of prostate tissue; by radiofrequency water vapor (steam) thermal therapy
D0411 Hba1c in-office point of service testing
D5511 Repair broken complete denture base, mandibular
D5512 Repair broken complete denture base, maxillary
D5611 Repair resin partial denture base, mandibular
D5612 Repair resin partial denture base, maxillary
D5621 Repair cast partial framework, mandibular
D5622 Repair cast partial framework, maxillary
D6096 Remove broken implant retaining screw
D6118 Implant/abutment supported interim fixed denture for edentulous arch - mandibular
D6119 Implant/abutment supported interim fixed denture for edentulous arch - maxillary
D7296 Corticotomy - one to three teeth or tooth spaces, per quadrant
D7297 Corticotomy - four or more teeth or tooth spaces, per quadrant
D7979 Non-surgical sialolithotomy
D8695 Removal of fixed orthodontic appliances for reasons other than completion of treatment
D9222 Deep sedation/general anesthesia - first 15 minutes
D9239 Intravenous moderate (conscious) sedation/analgesia - first 15 minutes
D9995 Teledentistry - synchronous; real-time encounter
D9996 Teledentistry - asynchronous; information stored and forwarded to dentist for subsequent review
E0953 Wheelchair accessory, lateral thigh or knee support, any type including fixed mounting hardware, each
E0954 Wheelchair accessory, foot box, any type, includes attachment and mounting hardware, each foot
G0511 Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month
G0512 Rural health clinic or federally qualified health center (rhc/fqhc) only, psychiatric collaborative care model (psychiatric cocm), 60 minutes or more of clinical staff time for psychiatric cocm services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm) and including services furnished by a behavioral health care manager and consultation with a psychiatric consultant, per calendar month
G0513 Prolonged preventive service(s) (beyond the typical service time of the primary procedure), in the office or other outpatient setting requiring direct patient contact beyond the usual service; first 30 minutes (list separately in addition to code for preventive service)
G0514 Prolonged preventive service(s) (beyond the typical service time of the primary procedure), in the office or other outpatient setting requiring direct patient contact beyond the usual service; each additional 30 minutes (list separately in addition to code g0513 for additional 30 minutes of preventive service)
G0515 Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes
G0516 Insertion of non-biodegradable drug delivery implants, 4 or more (services for subdermal rod implant)
G0517 Removal of non-biodegradable drug delivery implants, 4 or more (services for subdermal implants)
G0518 Removal with reinsertion, non-biodegradable drug delivery implants, 4 or more (services for subdermal implants)
G9868 Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use under the Next Generation ACO model, less than 10 minutes
G9869 Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use under the Next Generation ACO model, 10-20 minutes
G9870 Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use under the Next Generation ACO model, 20 or more minutes
G9890 Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity
G9891 Documentation of medical reason(s) for not performing a dilated macular examination
G9892 Documentation of patient reason(s) for not performing a dilated macular examination
G9893 Dilated macular exam was not performed, reason not otherwise specified
G9894 Androgen deprivation therapy prescribed/administered in combination with external beam radiotherapy to the prostate
G9895 Documentation of medical reason(s) for not prescribing/administering androgen deprivation therapy in combination with external beam radiotherapy to the prostate (e.g., salvage therapy)
G9896 Documentation of patient reason(s) for not prescribing/administering androgen deprivation therapy in combination with external beam radiotherapy to the prostate
G9897 Patients who were not prescribed/administered androgen deprivation therapy in combination with external beam radiotherapy to the prostate, reason not given
G9898 Patient age 65 or older in institutinal special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54, or 56 any time during the measurement period
G9899 Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed
G9900 Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified
G9901 Patient age 65 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54, or 56 any time during the measurement period
G9902 Patient screened for tobacco use and identified as a tobacco user
G9903 Patient screened for tobacco use and identified as a tobacco non-user
G9904 Documentation of medical reason(s) for not screening for tobacco use (e.g., limited life expectancy, other medical reason)
G9905 Patient not screened for tobacco use, reason not given
G9906 Patient identified as a tobacco user received tobacco cessation intervention (counseling and/or pharmacotherapy)
G9907 Documentation of medical reason(s) for not providing tobacco cessation intervention (e.g., limited life expectancy, other medical reason)
G9908 Patient identified as tobacco user did not receive tobacco cessation intervention (counseling and/or pharmacotherapy), reason not given
G9909 Documentation of medical reason(s) for not providing tobacco cessation intervention if identified as a tobacco user (eg, limited life expectancy, other medical reason)
G9910 Patients age 65 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 anytime during the measurement period
G9911 Clinically node negative (t1n0m0 or t2n0m0) invasive breast cancer before or after neoadjuvant systemic therapy
G9912 Hepatitis b virus (hbv) status assessed and results interpreted prior to initiating anti-tnf (tumor necrosis factor) therapy
G9913 Hepatitis b virus (hbv) status not assessed and results interpreted prior to initiating anti-tnf (tumor necrosis factor) therapy, reason not given
G9914 Patient receiving an anti-tnf agent
G9915 No record of hbv results documented
G9916 Functional status performed once in the last 12 months
G9917 Documentation of medical reason(s) for not performing functional status (e.g., patient is severely impaired and caregiver knowledge is limited, other medical reason)
G9918 Functional status not performed, reason not otherwise specified
G9919 Screening performed and positive and provision of recommendations
G9920 Screening performed and negative
G9921 No screening performed, partial screening performed or positive screen without recommendations and reason is not given or otherwise specified
G9922 Safety concerns screen provided and if positive then documented mitigation recommendations
G9923 Safety concerns screen provided and negative
G9924 Documentation of medical reason(s) for not providing safety concerns screen or for not providing recommendations, orders or referrals for positive screen (e.g., patient in palliative care, other medical reason)
G9925 Safety concerns screening not provided, reason not otherwise specified
G9926 Safety concerns screening positive screen is without provision of mitigation recommendations, including but not limited to referral to other resources
G9927 Documentation of system reason(s) for not prescribing warfarin or another fda-approved anticoagulation due to patient being currently enrolled in a clinical trial related to af/atrial flutter treatment
G9928 Warfarin or another fda-approved anticoagulant not prescribed, reason not given
G9929 Patient with transient or reversible cause of af (e.g., pneumonia, hyperthyroidism, pregnancy, cardiac surgery)
G9930 Patients who are receiving comfort care only
G9931 Documentation of cha2ds2-vasc risk score of 0 or 1
G9932 Documentation of patient reason(s) for not having records of negative or managed positive tb screen (e.g., patient does not return for mantoux (ppd) skin test evaluation)
G9933 Adenoma(s) or colorectal cancer detected during screening colonoscopy
G9934 Documentation that neoplasm detected is only diagnosed as traditional serrated adenoma, sessile serrated polyp, or sessile serrated adenoma
G9935 Adenoma(s) or colorectal cancer not detected during screening colonoscopy
G9936 Surveillance colonoscopy - personal history of colonic polyps, colon cancer, or other malignant neoplasm of rectum, rectosigmoid junction, and anus
G9937 Diagnostic colonoscopy
G9938 Patients age 65 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54, or 56 any time during the measurement period
G9939 Pathologists/dermatopathologists is the same clinician who performed the biopsy
G9940 Documentation of medical reason(s) for not on a statin (e.g., pregnancy, in vitro fertilization, clomiphene rx, esrd, cirrhosis, muscular pain and disease during the measurement period or prior year)
G9941 Back pain was measured by the visual analog scale (vas) within three months preoperatively and at three months (6 - 20 weeks) postoperatively
G9942 Patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminotomy
G9943 Back pain was not measured by the visual analog scale (vas) within three months preoperatively and at three months ( 6 - 20 weeks) postoperatively
G9944 Back pain was measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively
G9945 Patient had cancer, fracture or infection related to the lumbar spine or patient had idiopathic or congenital scoliosis
G9946 Back pain was not measured by the visual analog scale (vas) within three months preoperatively and at one year (9 to 15 months) postoperatively
G9947 Leg pain was measured by the visual analog scale (vas) within three months preoperatively and at three months (6 to 20 weeks) postoperatively
G9948 Patient had any additional spine procedures performed on the same date as the lumbar discectomy/laminotomy
G9949 Leg pain was not measured by the visual analog scale (vas) within three months preoperatively and at three months (6 to 20 weeks) postoperatively
G9954 Patient exhibits 2 or more risk factors for post-operative vomiting
G9955 Cases in which an inhalational anesthetic is used only for induction
G9956 Patient received combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively
G9957 Documentation of medical reason for not receiving combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively (e.g., intolerance or other medical reason)
G9958 Patient did not receive combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively
G9959 Systemic antimicrobials not prescribed
G9960 Documentation of medical reason(s) for prescribing systemic antimicrobials
G9961 Systemic antimicrobials prescribed
G9962 Embolization endpoints are documented separately for each embolized vessel and ovarian artery angiography or embolization performed in the presence of variant uterine artery anatomy
G9963 Embolization endpoints are not documented separately for each embolized vessel or ovarian artery angiography or embolization not performed in the presence of variant uterine artery anatomy
G9964 Patient received at least one well-child visit with a pcp during the performance period
G9965 Patient did not receive at least one well-child visit with a pcp during the performance period
G9966 Children who were screened for risk of developmental, behavioral and social delays using a standardized tool with interpretation and report
G9967 Children who were not screened for risk of developmental, behavioral and social delays using a standardized tool with interpretation and report
G9968 Patient was referred to another provider or specialist during the performance period
G9969 Provider who referred the patient to another provider received a report from the provider to whom the patient was referred
G9970 Provider who referred the patient to another provider did not receive a report from the provider to whom the patient was referred
G9974 Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity
G9975 Documentation of medical reason(s) for not performing a dilated macular examination
G9976 Documentation of patient reason(s) for not performing a dilated macular examination
G9977 Dilated macular exam was not performed, reason not otherwise specified
J0565 Injection, bezlotoxumab, 10 mg
J0604 Cinacalcet, oral, 1 mg, (for esrd on dialysis)
J0606 Injection, etelcalcetide, 0.1 mg
J1428 Injection, eteplirsen, 10 mg
J1555 Injection, immune globulin (cuvitru), 100 mg
J1627 Injection, granisetron, extended-release, 0.1 mg
J1726 Injection, hydroxyprogesterone caproate, (makena), 10 mg
J1729 Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
J2326 Injection, nusinersen, 0.1 mg
J2350 Injection, ocrelizumab, 1 mg
J3358 Ustekinumab, for intravenous injection, 1 mg
J7210 Injection, factor viii, (antihemophilic factor, recombinant), (afstyla), 1 i.u.
J7211 Injection, factor viii, (antihemophilic factor, recombinant), (kovaltry), 1 i.u.
J7296 Levonorgestrel-releasing intrauterine contraceptive system, (kyleena), 19.5 mg
J7345 Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg
J9022 Injection, atezolizumab, 10 mg
J9023 Injection, avelumab, 10 mg
J9203 Injection, gemtuzumab ozogamicin, 0.1 mg
J9285 Injection, olaratumab, 10 mg
K0553 Supply allowance for therapeutic continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service
K0554 Receiver (monitor), dedicated, for use with therapeutic glucose continuous monitor system
L3761 Elbow orthosis (eo), with adjustable position locking joint(s), prefabricated, off-the-shelf
L7700 Gasket or seal, for use with prosthetic socket insert, any type, each
L8625 External recharging system for battery for use with cochlear implant or auditory osseointegrated device, replacement only, each
L8694 Auditory osseointegrated device, transducer/actuator, replacement only, each
P9073 Platelets, pheresis, pathogen-reduced, each unit
P9100 Pathogen(s) test for platelets
Q0477 Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
Q2040 Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Q4176 Neopatch, per square centimeter
Q4177 Floweramnioflo, 0.1 cc
Q4178 Floweramniopatch, per square centimeter
Q4179 Flowerderm, per square centimeter
Q4180 Revita, per square centimeter
Q4181 Amnio wound, per square centimeter
Q4182 Transcyte, per square centimeter

 

Deleted Codes

HCPCS DESCRIPTION
A9599 Radiopharmaceutical, diagnostic, for beta-amyloid positron emission tomography (pet) imaging, per study dose, not otherwise specified
C9140 Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.
C9483 Injection, atezolizumab, 10 mg
C9484 Injection, eteplirsen, 10 mg
C9485 Injection, olaratumab, 10 mg
C9486 Injection, granisetron extended release, 0.1 mg
C9487 Ustekinumab, for intravenous injection, 1 mg
C9489 Injection, nusinersen, 0.1 mg
C9490 Injection, bezlotoxumab, 10 mg
C9491 Injection, avelumab, 10 mg
C9494 Injection, ocrelizumab, 1 mg
D5510 Repair broken complete denture base
D5610 Repair resin denture base
D5620 Repair cast framework
G0202 Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed
G0204 Diagnostic mammography, including computer-aided detection (cad) when performed; bilateral
G0206 Diagnostic mammography, including computer-aided detection (cad) when performed; unilateral
G0364 Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service
G0502 Initial psychiatric collaborative care management, first 70 minutes in the first calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: outreach to and engagement in treatment of a patient directed by the treating physician or other qualified health care professional; initial assessment of the patient, including administration of validated rating scales, with the development of an individualized treatment plan; review by the psychiatric consultant with modifications of the plan if recommended; entering patient in a registry and tracking patient follow-up and progress using the registry, with appropriate documentation, and participation in weekly caseload consultation with the psychiatric consultant; and provision of brief interventions using evidence-based techniques such as behavioral activation, motivational interviewing, and other focused treatment strategies
G0503 Subsequent psychiatric collaborative care management, first 60 minutes in a subsequent month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional, with the following required elements: tracking patient follow-up and progress using the registry, with appropriate documentation; participation in weekly caseload consultation with the psychiatric consultant; ongoing collaboration with and coordination of the patient's mental health care with the treating physician or other qualified health care professional and any other treating mental health providers; additional review of progress and recommendations for changes in treatment, as indicated, including medications, based on recommendations provided by the psychiatric consultant; provision of brief interventions using evidence-based techniques such as behavioral activation, motivational interviewing, and other focused treatment strategies; monitoring of patient outcomes using validated rating scales; and relapse prevention planning with patients as they achieve remission of symptoms and/or other treatment goals and are prepared for discharge from active treatment
G0504 Initial or subsequent psychiatric collaborative care management, each additional 30 minutes in a calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional (list separately in addition to code for primary procedure); (use g0504 in conjunction with g0502, g0503)
G0505 Cognition and functional assessment using standardized instruments with development of recorded care plan for the patient with cognitive impairment, history obtained from patient and/or caregiver, in office or other outpatient setting or home or domiciliary or rest home
G0507 Care management services for behavioral health conditions, at least 20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team
G8696 Antithrombotic therapy prescribed at discharge
G8697 Antithrombotic therapy not prescribed for documented reasons (e.g., patient had stroke during hospital stay, patient expired during inpatient stay, other medical reason(s)); (e.g., patient left against medical advice, other patient reason(s))
G8698 Antithrombotic therapy was not prescribed at discharge, reason not given
G8879 Clinically node negative (t1n0m0 or t2n0m0) invasive breast cancer
G8947 One or more neuropsychiatric symptoms
G8971 Warfarin or another oral anticoagulant that is fda approved not prescribed, reason not given
G8972 One or more high risk factors for thromboembolism or more than one moderate risk factor for thromboembolism
G9381 Documentation of medical reason(s) for not offering assistance with end of life issues (e.g., patient in hospice care, patient in terminal phase) during the measurement period
G9496 Documentation of reason for not detecting adenoma(s) or other neoplasm. (e.g., neoplasm detected is only diagnosed as traditional serrated adenoma, sessile serrated polyp, or sessile serrated adenoma
J1725 Injection, hydroxyprogesterone caproate, 1 mg
J9300 Injection, gemtuzumab ozogamicin, 5 mg
P9072 Platelets, pheresis, pathogen reduced or rapid bacterial tested, each unit
Q9984 Levonorgestrel-releasing intrauterine contraceptive system (kyleena), 19.5 mg
Q9985 Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
Q9986 Injection, hydroxyprogesterone caproate, (makena), 10 mg
Q9987 Pathogen(s) test for platelets
Q9988 Platelets, pheresis, pathogen-reduced, each unit
Q9989 Ustekinumab, for intravenous injection, 1 mg

 

Source

  • Transmittal 3843, CR 10202 dated August 18, 2017

 

Last Updated Mon, 08 Oct 2018 08:01:58 +0000